Literature DB >> 1549346

Two independent activation domains in c-Ets-1 and c-Ets-2 located in non-conserved sequences of the ets gene family.

J Schneikert1, Y Lutz, B Wasylyk.   

Abstract

The c-Ets-1 oncoprotein is a transcription activator that specifically binds to DNA. We show, using fusion proteins with heterologous DNA-binding domains, that chicken c-Ets-1 (p68) contains two independent activation domains. The N-terminal activation domain is absent in c-Ets-1 (p54) that is generated from an alternatively spliced mRNA. A closely related member of the ets gene family, c-Ets-2, also contains two separate activation domains. They lie in the regions of the protein that are least conserved with c-Ets-1, suggesting that the activating function will determine the different physiological roles of these two proteins. The activation domains of c-Ets-1 (p68) and -2 are separated by a moderately conserved region that does not activate on its own. These sequences appear to affect stimulation by the domains, suggesting that they regulate transcription activation. Competition experiments show that c-Ets-1 and -2 interact with a common limiting coactivator. These studies provide important clues about the physiological roles of closely related members of the ets gene family.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549346

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Sp100 interacts with ETS-1 and stimulates its transcriptional activity.

Authors:  Christine Wasylyk; Sophie E Schlumberger; Paola Criqui-Filipe; Bohdan Wasylyk
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

2.  Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter.

Authors:  Luciano De Haro; Ralf Janknecht
Journal:  Nucleic Acids Res       Date:  2002-07-01       Impact factor: 16.971

3.  The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.

Authors:  S W Hiebert; W Sun; J N Davis; T Golub; S Shurtleff; A Buijs; J R Downing; G Grosveld; M F Roussell; D G Gilliland; N Lenny; S Meyers
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

4.  Ets-1 regulates radial glia formation during vertebrate embryogenesis.

Authors:  Tomomi Kiyota; Akiko Kato; Yoichi Kato
Journal:  Organogenesis       Date:  2007-10       Impact factor: 2.500

5.  Interaction of Ets-1 and the POU-homeodomain protein GHF-1/Pit-1 reconstitutes pituitary-specific gene expression.

Authors:  A P Bradford; C Wasylyk; B Wasylyk; A Gutierrez-Hartmann
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

6.  The ETS family member ERM contains an alpha-helical acidic activation domain that contacts TAFII60.

Authors:  P A Defossez; J L Baert; M Monnot; Y de Launoit
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

7.  Context dependent transactivation domains activate the immunoglobulin mu heavy chain gene enhancer.

Authors:  B Erman; R Sen
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

8.  The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.

Authors:  M Carroll; M H Tomasson; G F Barker; T R Golub; D G Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

9.  Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment.

Authors:  Charles E Foulds; Mary L Nelson; Adam G Blaszczak; Barbara J Graves
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

10.  Structural characterization of the PIT-1/ETS-1 interaction: PIT-1 phosphorylation regulates PIT-1/ETS-1 binding.

Authors:  Kevin D Augustijn; Dawn L Duval; Rainer Wechselberger; Rob Kaptein; Arthur Gutierrez-Hartmann; Peter C van der Vliet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.